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Introduction
The RAS-ERK signaling pathway regulates several cell functions, including differentiation, senescence, proliferation and survival (1) . In normal cells this pathway is activated by receptor tyrosine kinases, and by hormone and cytokine receptors. However, in approximately 30% of human cancers, the pathway is constitutively activated because its components are either over-expressed or have acquired gain-of-function mutations. One constituent that is mutated in approximately 7-8% of human cancers is BRAF (2) , with mutations in this serine/threonine specific protein kinase being particularly common in melanoma (~45%), and thyroid (~40%), ovarian (~10%) and colorectal cancers (~15%) (www.sanger.ac.uk/genetics/CGP/cosmic/). BRAF, together with its close relatives ARAF and CRAF, is responsible for coupling signaling from the small G-protein RAS to the dual specificity kinase MEK, which in turn activates ERK, the third kinase in this cascade. ERK regulates the activity of many cellular proteins to control the cells' biological behavior.
However, when BRAF is mutated, the pathway is constitutively activated in a RAS-independent manner (1).
Over 100 different mutations have been described in BRAF in human cancer, but a glutamic acid for valine substitution at position 600 (V600E) is the most common and accounts for over 90% of the mutations that occur in cancer. V600E BRAF can induce transformation of mammalian cells, allowing them to grow in a growth factor-independent manner in vitro and as tumors in nude mice (2, 3) . Importantly, inhibition of V600E BRAF signaling blocks ERK activity and proliferation in vitro, and in vivo it blocks the growth of tumor xenografts in nude mice (4, 5) . These data validate V600E BRAF as an important therapeutic target in melanoma and the other cancers in which BRAF is mutated. Consequently, a number of drug discovery programs have been initiated to develop inhibitors of this mutant protein kinase.
Initial attempts to target V600E BRAF in melanoma proved disappointing, because although the multi-kinase inhibitor sorafenib was shown to inhibit V600E BRAF signaling in vitro, it failed to yield significant responses in patients in phase I/II clinical trials (4) (5) (6) (7) (8) . However, sorafenib is approximately 100-fold less active against V600E BRAF in cells (2-5 µM) than it is against the purified kinase (40 nM) in vitro (5) . Furthermore, sorafenib has been approved for use Table 1 ). Inhibitor 1t (CCT239065) was synthesized as described (14) . Drugs were dissolved in DMSO at 10 mM and diluted as required.
Molecular modeling
Inhibitor 1t was docked into BRAF (PDB code: UWH) using GOLD version 3.1.1 (15) . In order to prepare the receptor for docking, the crystal structure was protonated using the Protonate3D tool of MOE (Chemical Computing Group, Cambridge, UK), and the ligand and water molecules were then removed. The active site was defined using a radius of 10 Å from the backbone oxygen atom of Asp594 of the ATP binding pocket. Partial charges of the ligand were derived using the Charge-2 CORINA 3D package in TSAR 3.3, and their geometries optimized using the COSMIC module of TSAR. Ten docking solutions were generated per docking run with GOLD, and the best three stored for analysis.
Cell lysis and Western blotting
Cells lysates were prepared as described (16) 
Kinase assays
V600E BRAF protein was expressed, purified and kinase activity measured as described using 96 well-format assays and DELFIA detection 
Proliferation assays
The growth inhibitory activity of 1t in a panel of melanoma, colon and breast cancer cell lines was determined using sulforhodamine B (SRB) extractions and analysis were performed as described (20, 21) . 
Therapy studies

Pharmacodynamics (PD)
Mice bearing established, A375M or SW620 xenografts were prepared as for the therapy studies above. 
Results
We have developed a series of novel BRAF inhibitors (14, (22) (23) (24) (25) . One such compound called CCT239065 (henceforth referred to as 1t) with the Fig 1A) We have shown that close analogs of compound 1t are type II inhibitors and so bind to the inactive conformation of BRAF (24, 25) . Docking studies suggest that 1t also binds to the inactive conformation of BRAF, with the pyridopyrazin-3(4H)-one moiety forming two hydrogen bonds with the backbone of Cys532 of the hinge region (Fig 1D) . Three more H bonds are BPI pocket improves the selectivity of BRAF inhibitors (22, 24) , so the thiomethyl group is likely to contribute to both potency and selectivity of 1t.
In accordance with its in vitro selectivity, 1t inhibits the growth of cancer cell lines harboring V600D/E BRAF mutations, but is relatively ineffective in cell lines in which BRAF is wildtype (Fig 2A) . Concordant with this, 1t
induces a profound inhibition of DNA synthesis in mutant V600D BRAF cells but not in mutant KRAS cells (Fig 2B) . BRAF-expressing cells ( Fig   2D) .
To demonstrate its selectivity further, we show that after 24 h, 1t
potently inhibits MEK and ERK phosphorylation in V600D BRAF WM266.4 cells (10-100 nM) and this is accompanied by decreased expression of cyclin D1 (Fig 3A) , the transcription of which is regulated by the MAPK pathway (28) . In contrast, no such responses are observed in BRAF wild-type D35 melanoma cells at concentrations up to 10 µM (Fig 3B) . Furthermore, in KRAS mutant SW620 colorectal carcinoma cells, 1t induces a profound increase in MEK and ERK phosphorylation and this is accompanied by increased cyclin D1 expression ( Fig 3C) . We attribute this effect to the transactivation of CRAF by BRAF through a mechanism involving RAS-dependent BRAF:CRAF heterodimerization, which promotes activation of the downstream signaling cascade as we and others recently reported (29, 30) . Notably, the increase in pathway activation is accompanied by a small increase in proliferation driven by 1t in SW620 cells (Fig 3D) . Fig   5C) . Curiously, we also do not see enhanced tumor growth in this model, despite the increase in MEK phosphorylation induced in these tumors ( Fig   5D) . Importantly, 1t is well tolerated as judged by the observation that the continuous daily dosing used in these therapy experiments does not cause any deaths and causes less than 10% body weight loss over the course of the treatment (Supplemental Figure 1) . (29) .
Our data also reveal that sensitivity to BRAF drugs may not be determined by BRAF mutation status alone. For example,
V600E
BRAF mutant HT29 cells were less sensitive to 1t than the majority of the other BRAF mutant cell lines, whereas SKMEL23 cells were considerably more sensitive to 1t than the other BRAF/RAS wildtype cells. Similar responses have been previously reported in these lines using another BRAF inhibitor, GDC-0879 (32) . It has been suggested that HT29 cells are resistant to drugs of this class because they express high levels of glucuronosyltransferase that could metabolize these drugs (33) . Conversely, it is feasible that SKMEL23 cells have, as yet unidentified, genetic alterations that confer sensitivity to this class of drug. These observations highlight the fact that sensitivity to specific drugs may not always be determined by a single mutation, and that other genetic aberrations in specific cancer cells can modify cell responses (29) .
Nevertheless, together, our data suggest that in the cellular context, 1t selectively inhibits oncogenic BRAF over CRAF or the other kinases that are critical for proliferation of BRAF wildtype or RAS mutant cells. (29) . 1t is also well tolerated, with no adverse effects observed following daily drug treatment for extended periods, and we also did not observe any skin lesions of the type described with another BRAF inhibitor, GDC-0879 (29) . This also shows that off-target activity against kinases such as SRC, LCK or p38α inhibition was not inherently toxic.
Our modelling data suggest that 1t binds to the inactive conformation (type II inhibitor) of BRAF. In this, 1t is similar to sorafenib and RAF265, but distinct from agents such as SB590885 and PLX4720/PLX4032 that bind to the active or 'active-like' conformation (type I inhibitors) (11, 12, 34, 35) . 
